390 related articles for article (PubMed ID: 23982172)
1. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma.
Ben-Batalla I; Schultze A; Wroblewski M; Erdmann R; Heuser M; Waizenegger JS; Riecken K; Binder M; Schewe D; Sawall S; Witzke V; Cubas-Cordova M; Janning M; Wellbrock J; Fehse B; Hagel C; Krauter J; Ganser A; Lorens JB; Fiedler W; Carmeliet P; Pantel K; Bokemeyer C; Loges S
Blood; 2013 Oct; 122(14):2443-52. PubMed ID: 23982172
[TBL] [Abstract][Full Text] [Related]
2. Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?
Janning M; Ben-Batalla I; Loges S
Expert Rev Hematol; 2015 Apr; 8(2):135-8. PubMed ID: 25578023
[TBL] [Abstract][Full Text] [Related]
3. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S
Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360
[TBL] [Abstract][Full Text] [Related]
4. Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma.
Waizenegger JS; Ben-Batalla I; Weinhold N; Meissner T; Wroblewski M; Janning M; Riecken K; Binder M; Atanackovic D; Taipaleenmaeki H; Schewe D; Sawall S; Gensch V; Cubas-Cordova M; Seckinger A; Fiedler W; Hesse E; Kröger N; Fehse B; Hose D; Klein B; Raab MS; Pantel K; Bokemeyer C; Loges S
Leukemia; 2015 Mar; 29(3):696-704. PubMed ID: 25102945
[TBL] [Abstract][Full Text] [Related]
5. AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia.
Vandewalle N; Satilmis H; Verheye E; Fan R; Wang Y; De Groof TWM; Bridoux J; Kerre T; De Beule N; De Becker A; De Bruyne E; Menu E; Vanderkerken K; Breckpot K; Devoogdt N; De Veirman K
Theranostics; 2024; 14(7):2656-2674. PubMed ID: 38773967
[No Abstract] [Full Text] [Related]
6. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
Park IK; Mishra A; Chandler J; Whitman SP; Marcucci G; Caligiuri MA
Blood; 2013 Mar; 121(11):2064-73. PubMed ID: 23321254
[TBL] [Abstract][Full Text] [Related]
7. Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer.
Avilla E; Guarino V; Visciano C; Liotti F; Svelto M; Krishnamoorthy G; Franco R; Melillo RM
Cancer Res; 2011 Mar; 71(5):1792-804. PubMed ID: 21343401
[TBL] [Abstract][Full Text] [Related]
8. Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin.
Jin Y; Nie D; Li J; Du X; Lu Y; Li Y; Liu C; Zhou J; Pan J
Clin Cancer Res; 2017 Jun; 23(11):2842-2855. PubMed ID: 27852702
[No Abstract] [Full Text] [Related]
9. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib
Dumas PY; Naudin C; Martin-Lannerée S; Izac B; Casetti L; Mansier O; Rousseau B; Artus A; Dufossée M; Giese A; Dubus P; Pigneux A; Praloran V; Bidet A; Villacreces A; Guitart A; Milpied N; Kosmider O; Vigon I; Desplat V; Dusanter-Fourt I; Pasquet JM
Haematologica; 2019 Oct; 104(10):2017-2027. PubMed ID: 30923103
[TBL] [Abstract][Full Text] [Related]
10. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.
Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO
Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.
Kariolis MS; Miao YR; Diep A; Nash SE; Olcina MM; Jiang D; Jones DS; Kapur S; Mathews II; Koong AC; Rankin EB; Cochran JR; Giaccia AJ
J Clin Invest; 2017 Jan; 127(1):183-198. PubMed ID: 27893463
[TBL] [Abstract][Full Text] [Related]
12. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
Park IK; Mundy-Bosse B; Whitman SP; Zhang X; Warner SL; Bearss DJ; Blum W; Marcucci G; Caligiuri MA
Leukemia; 2015 Dec; 29(12):2382-9. PubMed ID: 26172401
[TBL] [Abstract][Full Text] [Related]
13. Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia.
Niu X; Rothe K; Chen M; Grasedieck S; Li R; Nam SE; Zhang X; Novakovskiy GE; Ahn YH; Maksakova I; Lai S; Zhang H; Yan J; Liu H; Zhao Y; Wu D; Ge Y; Wasserman WW; Rouhi A; Kuchenbauer F; Yip CK; Zhang Z; Jiang X
Blood; 2021 Jul; 137(26):3641-3655. PubMed ID: 33786587
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of soluble Axl and Mer receptor tyrosine kinases negatively correlates with Gas6 in established multiple sclerosis lesions.
Weinger JG; Omari KM; Marsden K; Raine CS; Shafit-Zagardo B
Am J Pathol; 2009 Jul; 175(1):283-93. PubMed ID: 19541935
[TBL] [Abstract][Full Text] [Related]
15. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia.
Hong CC; Lay JD; Huang JS; Cheng AL; Tang JL; Lin MT; Lai GM; Chuang SE
Cancer Lett; 2008 Sep; 268(2):314-24. PubMed ID: 18502572
[TBL] [Abstract][Full Text] [Related]
16. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities.
Lew ED; Oh J; Burrola PG; Lax I; Zagórska A; Través PG; Schlessinger J; Lemke G
Elife; 2014 Sep; 3():. PubMed ID: 25265470
[TBL] [Abstract][Full Text] [Related]
17. Antibody-mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors in vivo.
Moody G; Belmontes B; Masterman S; Wang W; King C; Murawsky C; Tsuruda T; Liu S; Radinsky R; Beltran PJ
Int J Cancer; 2016 Sep; 139(6):1340-9. PubMed ID: 27170265
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer.
Tanaka M; Siemann DW
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576116
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival.
Gustafsson A; Martuszewska D; Johansson M; Ekman C; Hafizi S; Ljungberg B; Dahlbäck B
Clin Cancer Res; 2009 Jul; 15(14):4742-9. PubMed ID: 19567592
[TBL] [Abstract][Full Text] [Related]
20. TAM receptors Tyro3 and Mer as novel targets in colorectal cancer.
Schmitz R; Valls AF; Yerbes R; von Richter S; Kahlert C; Loges S; Weitz J; Schneider M; Ruiz de Almodovar C; Ulrich A; Schmidt T
Oncotarget; 2016 Aug; 7(35):56355-56370. PubMed ID: 27486820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
